علاج مرض الكلى المزمن مع الألبومينية المتزايدة بشكل معتدل أو شديد دون داء السكري

References

DOI: 10.1016/j.kint.2023.10.018

1. We recommend starting renin-angiotensin-system inhibitors (RASi) (angiotensin-converting enzyme inhibitor [ACEi] or angiotensin II receptor blocker [ARB]) for people with CKD and severely increased albuminuria (G1–G4, A3) without diabetes (1B).
2. We suggest starting RASi (ACEi or ARB) for people with CKD and moderately increased albuminuria (G1–G4, A2) without diabetes (2C).
3. RASi (ACEi or ARB) should be administered using the highest approved dose that is tolerated to achieve the benefits described because the proven benefits were achieved in trials using these doses.